BCAB BioAtla, Inc.
Biological Products, (No Diagnostic Substances) · OTC · SEC CIK 1826892 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY63.6%
TTM EPS YoY177.0%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE—
ROA-277.1%
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets4,031.1%
Debt / equity—
Current ratio0.05x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.62x
Accruals ratio-105.8%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | — | — | — | — | $300,000 |
| R&D expense | $43.57M | $63.09M | $103.73M | $79.35M | $58.27M |
| SG&A expense | $17.73M | $21.85M | $25.96M | $28.79M | $38.42M |
| Operating income | -$59.30M | -$73.94M | -$129.69M | -$108.14M | -$96.44M |
| Interest expense | — | — | — | $0 | $3,000 |
| Income tax | $0 | $0 | $0 | $0 | $0 |
| Net income | -$59.61M | -$69.78M | -$123.46M | -$106.48M | -$95.40M |
| EBITDA | -$58.93M | -$73.02M | -$128.47M | -$106.94M | -$95.11M |
| EPS (basic) | -1.01 | -1.44 | -2.58 | -2.74 | -2.76 |
| EPS (diluted) | -1.01 | -1.44 | -2.58 | -2.74 | -2.76 |
| Weighted avg. shares (diluted) | 58.83M | 48.57M | 47.78M | 38.93M | 34.56M |
| Balance sheet | |||||
| Cash & equivalents | $7.12M | $49.05M | $111.47M | $215.51M | $244.98M |
| Receivables | $0 | — | — | — | — |
| Current assets | $8.01M | $51.23M | $116.41M | $220.43M | $247.29M |
| PP&E, net | $120,000 | $678,000 | $1.60M | $2.73M | $3.68M |
| Total assets | $13.83M | $52.42M | $119.66M | $225.74M | $254.42M |
| Current liabilities | $21.92M | $14.54M | $28.34M | $23.13M | $19.81M |
| Total liabilities | $50.02M | $38.16M | $48.99M | $45.40M | $43.60M |
| Shareholders' equity | -$36.19M | $14.27M | $70.67M | $180.34M | $210.82M |
| Shares outstanding | 1.27M | 58.10M | 48.08M | 46.34M | 35.80M |
| Cash flow statement | |||||
| Operating cash flow | -$48.20M | -$71.94M | -$104.02M | -$90.42M | -$62.21M |
| Investing cash flow | — | $0 | -$98,000 | -$265,000 | -$924,000 |
| Financing cash flow | $6.28M | $9.51M | $77,000 | $61.21M | $69.51M |
| Depreciation & amortization | $373,000 | $925,000 | $1.22M | $1.20M | $1.33M |
| Stock-based compensation | $5.43M | $8.92M | $13.54M | $14.56M | $25.12M |
Free plan shows the latest 5 periods; Pro shows all 7 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.